Protective effects of taurine on doxorubicin-induced acute hepatotoxicity through suppression of oxidative stress and apoptotic responses

Anti-Cancer Drugs

Volumn 27, Issue 1, 2016, Pages 17-23

  Nagai, Katsuhito ^a   Fukuno, Shuhei ^a   Oda, Ayano ^a   Konishi, Hiroki ^a  

^a OSAKA OHTANI UNIVERSITY   (Japan)

Author keywords

Anthracycline; Apoptotic response; Hepatotoxicity; Oxidative stress; Taurine

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CASPASE 3; DOXORUBICIN; FAS ANTIGEN; GLUTATHIONE; LACTATE DEHYDROGENASE; LIVER PROTECTIVE AGENT; PROTEIN BAX; SUPEROXIDE DISMUTASE; TAURINE; ANTINEOPLASTIC ANTIBIOTIC;

ACUTE DISEASE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER PROTECTION; LIVER TOXICITY; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; UPREGULATION; WEIGHT REDUCTION; ANIMAL; DRUG EFFECTS; DRUG-INDUCED LIVER INJURY; METABOLISM; PATHOLOGY;

ALANINE TRANSAMINASE; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; ASPARTATE AMINOTRANSFERASES; DOXORUBICIN; DRUG-INDUCED LIVER INJURY; GLUTATHIONE; L-LACTATE DEHYDROGENASE; MALE; MICE; OXIDATIVE STRESS; SUPEROXIDE DISMUTASE; TAURINE;

EID: 84948389237     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000299     Document Type: Article

References (28)

1. Szulawska A, Czyz M. Molecular mechanisms of anthracyclines action. Postepy Hig Med Dosw (Online) 2006; 60:78-100.
2. Zhang Y, Shi J, Li Y, Wei L. Cardiomyocyte death in doxorubicin-induced cardiotoxicity. Arch Immunol Ther Exp (Warsz) 2009; 57:435-445.
3. Kalender Y, Yel M, Kalender S. Doxorubicin hepatotoxicity and hepatic free radical metabolism in rats. The effects of vitamin E and catechin. Toxicology 2005; 209:39-45.
4. Bardi E, Bobok I, Olah AV, Kappelmayer J, Kiss C. Anthracycline antibiotics induce acute renal tubular toxicity in children with cancer. Pathol Oncol Res 2007; 13:249-253.
5. Zhao X, Zhang J, Tong N, Chen Y, Luo Y. Protective effects of berberine on doxorubicin-induced hepatotoxicity in mice. Biol Pharm Bull 2012; 35:796-800.
6. Damodar G, Smitha T, Gopinath S, Vijayakumar S, Rao Y. An evaluation of hepatotoxicity in breast cancer patients receiving injection doxorubicin. Ann Med Health Sci Res 2014; 4:74-79.
7. Chatterjee K, Zhang J, Honbo N, Karliner JS. Doxorubicin cardiomyopathy. Cardiology 2010; 115:155-162.
8. Kassner N, Huse K, Martin H, Godtel-Armbrust U, Metzger A, Meineke I, et al. Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver. Drug Metab Dispos 2008; 36:2113-2120.
9. Nagai K, Oda A, Konishi H. Theanine prevents doxorubicin-induced acute hepatotoxicity by reducing intrinsic apoptotic response. Food Chem Toxicol 2015; 78:147-152.
10. Satoh H, Sperelakis N. Review of some actions of taurine on ion channels of cardiac muscle cells and others. Gen Pharmacol 1998; 30:451-463.
11. Cunningham C, Tipton KF, Dixon HBF. Conversion of taurine into N-chlorotaurine (taurine chloramine) and sulphoacetaldehyde in response to oxidative stress. Biochem J 1998; 330 (Pt 2):939-945.
12. Niittynen L, Nurminen M, Korpela R, Vapaatalo H. Role of arginine, taurine and homocysteine in cardiovascular diseases. Ann Med 1999; 31:318-326.
13. Invernizzi P, Setchell KDR, Crosignani A, Battezzati PM, Larqhi A, O'Connell NC, et al. Differences in the metabolism and disposition of ursodeoxycholic acid and of its taurine-conjugated species in patients with primary biliary cirrhosis. Hepatology 1999; 29:320-327.
14. Ito T, Muraoka S, Takahashi K, Fujio Y, Schaffer SW, Azuma J. Beneficial effect of taurine treatment against doxorubicin-induced cardiotoxicity in mice. Adv Exp Med Biol 2009; 643:65-74.
15. Das J, Ghosh J, Manna P, Sil PC. Taurine protects rat testes against doxorubicin-induced oxidative stress as well as p53, Fas and caspase 12-mediated apoptosis. Amino Acids 2012; 42:1839-1855.
16. O'Connel MJ. A phase III trial of 5-fluorouracil and leucovolin in the treatment of advanced colorectal cancer. Cancer 1998; 63:1026-1030.
17. Ichinose Y, Takanashi N, Yano T, Asoh H, Yokoyama H, Tayama K, et al. A phase II trial of oral tegafur and uracil plus cisplatin in patients with inoperable nonsmall cell lung cancer. Cancer 1995; 75:2677-2680.
18. Ramakrishnan G, Raghavendran HR, Vinodhkumar R, Devaki T. Suppression of N-nitrosodiethylamine induced hepatocarcinogenesis by silymarin in rats. Chem Biol Interact 2006; 161:104-114.
19. Vasquez-Garzon VR, Arellanes-Robledo J, Garcia-Roman R, Aparicio-Rautista DI, Villa-Trevino S. Inhibition of reactive oxygen species and preneoplastic lesions by quercetin through an antioxidant defense mechanism. Free Radic Res 2009; 43:128-137.
20. Arola OJ, Saraste A, Pulkki K, Kallajoki M, Parvinen M, Voipio-Pulkki LM. Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res 2000; 60:1789-1792.
21. Beere HM,Wolf BB, Cain K, Mosser DD, Mahboubi A, Kuwana T, et al. Heatshock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. Nat Cell Biol 2000; 2:469-475.
22. Müller I, Niethammer D, Bruchelt G. Anthracycline-derived chemotherapeutics in apoptosis and free radical cytotoxicity (Review). Int J Mol Med 1998; 1:491-494.
23. Petak I, Tillman DM, Houghton JA. p53 dependence of Fas induction and acute apoptosis in response to 5-fluorouracil-leucovorin in human colon carcinoma cell lines. Clin Cancer Res 2000; 6:4432-4441.
24. Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M, Green DR. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004; 303:1010-1014.
25. Gambino V, De Michele G, Venezia O, Migliaccio P, Dal'Olio V, Bernard L, et al. Oxidative stress activates a specific p53 transcriptional response that regulates cellular senescence and aging. Aging Cell 2013; 12:435-445.
26. Sugiyama T, Sadzuka Y. Theanine, a specific glutamate derivative in green tea, reduces the adverse reactions of doxorubicin by changing the glutathione level. Cancer Lett 2004; 212:177-184.
27. Sadzuka Y, Matsuura M, Sonobe T. The effect of taurine, a novel biochemical modulator, on the antitumor activity of doxorubicin. Biol Pharm Bull 2009; 32:1584-1587.
28. Sved DW, Godsey JL, Ledyard SL, Mahoney AP, Stetson PL, Ho S, et al. Absorption, tissue distribution, metabolism and elimination of taurine given orally to rats. Amino Acids 2007; 32:459-466.